TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Beyond Air ( (XAIR) ) is now available.
On November 21, 2025, Doug Larson, the Chief Financial Officer of Beyond Air, Inc., announced his resignation effective December 5, 2025, to pursue another opportunity. His departure was amicable and not due to any disagreements with the company. During his tenure, Larson played a significant role in transitioning Beyond Air to a commercial business, notably with the launch of LungFit PH and the establishment of subsidiaries Beyond Cancer and NeuroNOS. The company has initiated a search for a permanent successor, with Duke Drewell, the current Controller, stepping in as interim CFO. Larson will remain in an advisory role until the end of 2025 to ensure a smooth transition.
The most recent analyst rating on (XAIR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
Beyond Air’s overall stock score is primarily impacted by significant financial challenges, including negative profitability and high leverage. Technical indicators also signal bearish momentum. While the earnings call provided some positive insights on revenue growth and global expansion, these are overshadowed by operational inefficiencies and leadership transitions.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval for its LungFit PH system and is advancing other LungFit systems in clinical trials for severe lung infections. Beyond Air is also involved in pre-clinical programs for neurological disorders and cancer treatment through its affiliates.
Average Trading Volume: 3,288,681
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.65M
Find detailed analytics on XAIR stock on TipRanks’ Stock Analysis page.